← NovaBay Pharmaceuticals, Inc. (NBY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
NovaBay Pharmaceuticals, Inc. (NBY)
Pharmaceutical Preparations · market cap $52M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
6
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
NovaBay Pharmaceuticals (NBY) is a micro-cap, Emeryville-based clinical-stage biopharmaceutical company with 13 employees and a ~$52M market cap, focused on eye care and anti-infective products. Its commercial assets include Avenova (FDA-cleared for blepharitis lid/lash hygiene) and NeutroPhase (necrotizing fasciitis), while its lead pipeline candidate is CD07223 1.5% Topical Gel in Phase 3 for impetigo. The company carries a broad but early pipeline across conjunctivitis, bacteriuria, and urinary catheter indications, all at Phase 2, with no near-term catalysts publicly calendared.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NVC-422 | Phase 2 | Impetigo |
| Auriclosene Solution 0.3% | Phase 2 | Bacterial Conjunctivitis |
| NVC-422 Solution, 0.3% | Phase 2 | Adenoviral Conjunctivitis |
| sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate | Phase 2 | Asymptomatic Bacteriuria |
| NVC-422, 0.2% | Phase 2 | Urinary Catheter Blockage and Encrustation |
| Experimental: CD07223 1.5 % Topical Gel BID | Phase 3 | Impetigo |
Price & technical context
3-month
-93.1%
6-month
+42.3%
12-month
+230.5%
52-wk range
$0.47–$95.80
vs 50-day MA
-51.8%
vs 200-day MA
-70.6%
Realized vol
280.4%
Max drawdown
-98.8%
Daily closes through 2026-04-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NBY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.